by John Conrad | Jun 8, 2026 | Member News
A City Club of Chicago panel put longevity science on the civic agenda — and Illinois is already positioning to lead. A few years ago, longevity science lived mostly in academic journals and Silicon Valley pitch decks. Today, it’s a topic serious enough to draw...
by John Conrad | Jun 8, 2026 | iBIO in the News, iBIO News
Chicagoland has earned a spot on Genetic Engineering & Biotechnology News’ annual ranking of the Top 10 U.S. Biopharma Clusters, a recognition that reflects the region’s growing momentum across research, investment, and industry expansion. GEN ranks clusters...
by John Conrad | Jun 1, 2026 | iBIO News, Policy News
The passage of HB 4327 is a significant and long-overdue win for transparency, accountability, and — most importantly — for Illinois patients. For the first time, Illinois will have an independent, standardized accounting of how the 340B program actually operates in...
by John Conrad | May 13, 2026 | iBIO News
iBIO members have ongoing access to the monthly GBG Grant Reports, provided through iBIO’s partnership with GBG (Grants-to-Growth) / G2G Consulting. This month’s report features 170 funding opportunities across a wide range of scientific and medical fields, plus...
by John Conrad | Apr 24, 2026 | Policy News
Statement from John Conrad, President & CEO, iBIO “The FDA’s recent announcement advancing a more predictable Medicare coverage pathway for breakthrough medical technologies marks an important step toward addressing one of the most persistent challenges in patient...
